{"Clinical Trial ID": "NCT02435680", "Intervention": ["INTERVENTION 1:", "All MCS110+Carboplatin+Gemcitabine", "All patients treated with SCS110 with intravenous infusion of 10 mg/kg on day 1 and days 1 and 8", "INTERVENTION 2:", "Carboplatin+Gemcitabine", "Gemcitabine: Intravenous infusion 1000 mg/m2 Days 1 and 8 Carboplatin: Intravenous infusion AUC 2 Days 1 and 8"], "Eligibility": ["Incorporation criteria:", "\u2022 Adult women (18 years old) with advanced NBTC.", "\u00b7 Histological or cytological evidence of negative breast cancer of estrogen receptors (ER-), negative progesterone receptor (PgR-) and negative human epidermal growth factor of receptor 2 (HER2-) by local laboratory tests based on the latest tumour tissues available.", "\u00b7 Negativity ER/PgR to follow local guidelines", "If IHC HER2 2+, a negative FISH test is required", "A pre-treatment tumour biopsy demonstrating a high level of AMR, evaluated by the central laboratory", "Patients should have:", "At least one measurable injury by RECIST 1.1. (Note: Measurable lesions include lytic or mixed bone lesions (lytics + blasts), with an identifiable soft component that meets the measurability criteria.)", "- Exclusion criteria:", "- Prior adjuvant/neoadjuvant chemotherapy is allowed (carboplatin, cisplatin or gemcitabine only if > 12 months have elapsed since the last administration).", "Treatment of underlying malignancy within 2 weeks prior to initiation of study treatment:", "- Chemotherapy, biological therapy (antibodies and biologically targeted small molecules)", "Radiotherapy", "Major surgery", "Patients receiving concomitant immunosuppressants or chronic corticosteroids (prednisone 10 mg or equivalent) at the time of the first study dose.", "A clinically significant cardiovascular disease, such as uncontrolled or symptomatic arrhythmia, congestive heart failure or myocardial infarction within 6 months of screening.", "\u2022 Known history of human immunodeficiency virus or active hepatitis virus infection or any uncontrolled active systemic infection.", "In patients with the following biological values during screening and on the first day of predose:", "Absolute neutrophil count (ANC) < 1.5x109/L", "Hemoglobin < 9 g/dL", "\u2014 Blisters < 100x109/L", "Serum creatinine > 1.5 x ULN", "Total serum bilirubin > 1.5 x ULN", "AST/SGOT and ALT/SGPT > 3.0 x LSN"], "Results": ["Performance measures:", "According to RECIST v1.1, progression-free survival (PFS) (according to the evaluation of local researchers)", "The results of the PFS presented for all patients treated with SCS110 (with and without day 8 dose), in accordance with the Phase 2 study plan.", "Time limit: 4 years", "Results 1:", "- Arm/group title: All MCS110+Carboplatin+Gemcitabine", "All patients treated with SCS110 with intravenous infusion of 10 mg/kg on day 1 and days 1 and 8", "Total number of participants analysed: 34", "Median (90% confidence interval)", "Unit of measure: month 5.6 (4.5 to 8.7)", "Results 2:", "Title of arm/group: Carboplatin+Gemcitabine", "Gemcitabine: Intravenous infusion 1000 mg/m2 Days 1 and 8 Carboplatin: Intravenous infusion AUC 2 Days 1 and 8", "Total number of participants analysed: 16", "Median (90% confidence interval)", "Unit of measure: month 5.5 (3.5 to 7.5)"], "Adverse Events": ["Undesirable Events 1:", "Total: 10/19 (52.63 per cent)", "Anemia 0/19 (0.00 %)", "1/19 (5.26%)", "Thrombocytopenia 0/19 (0.00 %)", "Myocardial Irchaemia 0/19 (0.00 %)", "Nausea 0/19 (0.00 %)", "1/19 (5.26%)", "Vomiting 0/19 (0.00 %)", "- Fatigue 0/19 (0.00 %)", "General Oedema 1/19 (5.26%)", "Pyrexia 1/19 (5.26%)", "1/19-related infection (5.26 per cent)", "Adverse Events 2:", "Total: 7/15 (46.67 per cent)", "Anemia 1/15 (6.67 per cent)", "Atypical haemolytic uremic syndrome 0/15 (0.00 %)", "Thrombocytopenia 3/15 (20.00 per cent)", "Myocardial Ischemia 1/15 (6.67 per cent)", "Nausea 1/15 (6.67 per cent)", "- Obstructive pancreatitis 0/15 (0.00 %)", "- Vomiting 2/15 (13.33 per cent)", "Fatigue 1/15 (6.67 per cent)", "Generalised oedema 0/15 (0.00 %)", "Pyrexia 0/15 (0.00 %)", "- Device-related infection 0/15 (0.00 per cent)"]}